A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study ofPatidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal CellCarcinomas (BCCs) in Subjects with Basal Cell Nevus

Project: Research project

Description

A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Basal Cell Nevus
StatusActive
Effective start/end date8/27/188/31/23

Funding

  • PELLEPHARM, INC.

Fingerprint

Nevus
Basal Cell Carcinoma
Gels
Safety